Cardiac Biomarkers in Pediatric Cardiomyopathy (PCM Biomarkers)

Learn more about:
Related Clinical Trial
Evaluation of the CIRCULATE Catheter for Transcoronary Administration of Pharmacologic and Cell-based Agents Intraventricular Stasis In Cardiovascular Disease Dilated Cardiomyopathy-Cardiac Magnetic Resonance (DCM-CMR) Ancillary Study A 10-Minute Cardiovascular Magnetic Resonance Protocol for Cardiac Disease CorCinch-HF Repair System in Patients Who Present With Symptomatic Non-Ischemic or Ischemic Dilated Cardiomyopathy Early Administration of Ivabradine in Children With Heart Failure Metabolomics and Microbiomics in Cardiovascular Diseases Mannheim TORCH-Plus is a Registry for Patients With Cardiomyopathies and Serves as Source for Cardiovascular Research Studies Risk Stratification in Children and Adolescents With Primary Cardiomyopathy Pediatric Cardiomyopathy Mutation Analysis German Centre for Cardiovascular Research Cardiomyopathy Register Hemodynamic Evaluation of Preload Responsiveness in Children by Using PiCCO An Integrative-“Omics” Study of Cardiomyopathy Patients for Diagnosis and Prognosis in China Metabolomic Study of All-age Cardiomyopathy Coronary Artery Disease and Coronary Microvascular Disease in Cardiomyopathies Registry The Genetics of Cardiomyopathy and Heart Failure Inflammation, Cardiac Sympathetic Innervation, and Arrhythmic Sudden Death Comparative Effectiveness Research to Assess the Use of Primary ProphylacTic Implantable Cardioverter Defibrillators in Europe Randomized Trial of Interventions to Improve Warfarin Adherence Testing Strategies to Improving Warfarin Adherence Prospective Study Looking at Quality of Life Measures in Non-ischaemic Cardiomyopathy After Mitral Valve Repair Left Cardiac Sympathetic Denervation for Cardiomyopathy Feasibility Pilot Study The Cardiovascular Genetic and Therapeutic Implications of Muscular Dystrophy A Randomized Trial of Carvedilol in Chronic Chagas Cardiomyopathy Role of Endothelial Function, Muscular Fitness and Metabolism in Functional Activity in Patients With Chronic Heart Failure (CHF) Echo Assessment of Intraventricular Dyssynchrony Brain Function and Perfusion in Patients With Heart Failure Molecular and Imaging Studies of Cardiovascular Health and Disease Genotype-Phenotype Associations in Pediatric Cardiomyopathy (PCM GENES) Optimizing Left Ventricular Lead To Improve Cardiac Output Using Ripple Mapping to Guide Substrate Ablation of Scar Related Ventricular Tachycardia. Long-term Evaluation of Patients Receiving Bone Marrow-derived Cell Administration for Heart Disease Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-491 Efficacy and Safety Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure Harefield Recovery Protocol Study for Patients With Refractory Chronic Heart Failure ACC – Atrial Contribution to CRT Follow-up Safety Trial in Children With Chronic Heart Failure Therapy Receiving Orodispersible Minitablets of Enalapril Non-Invasive Evaluation of Myocardial Stiffness by Elastography in Pediatric Cardiology (Elasto-Pédiatrie) Manganese-Enhanced Magnetic Resonance Imaging of the Myocardium Efficacy of Implantable Cardioverter Defibrillator in Patients With Non-ischemic Systolic Heart Failure on Mortality Cardiac Biomarkers in Pediatric Cardiomyopathy (PCM Biomarkers) Arrhythmia Prediction Trial Exome Sequencing Study in Cardiomyopathy to Identify New Risk Variants A Single Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of MYK-491 Exercise Stress MRI to Evaluate Aortic Function (Compliance, Distensibility, Pulse Wave Velocity) and Left Ventricular Function : Validation in Healthy Volunteers and in Selected Patients. A Pilot Study. Randomized Clinical Trial of Intravenous Infusion Umbilical Cord Mesenchymal Stem Cells on Cardiopathy Observational Trial of Cardiotoxicity in Patients Undergoing Chemotherapy. A Pivotal Trial to Establish the Efficacy and Safety of Algisyl in Patients With Moderate to Severe Heart Failure Effect of Rosuvastatin on Left Ventricular Remodeling Intraventricular Stasis in Non Ischemic Dilated Myocardiopathy Assessment of Right Ventricular Function in Advanced Heart Failure An Open Label Rollover Trial for Patients Randomized to the Control Group of Study LSH-10-001 Optimized Biventricular Pacing Allograft Recipients BiPAP for Cardiomyopathy With Central Sleep Apnea Relationship Between Abnormalities of Desmin Cytoskeleton, Mitochondrial Activity and Expression of Ubiquitin in Aspect of Pathogenesis of Heart Failure and Prognosis Effect of Aldosterone on Energy Starvation in Heart Failure Resveratrol: A Potential Anti- Remodeling Agent in Heart Failure, From Bench to Bedside Therapy With Verapamil or Carvedilol in Chronic Heart Failure Effect of Beta-blockers on Structural Remodeling and Gene Expression in the Failing Human Heart Training Study to Evaluate the Benefit of Exercise for Patients With Chronic Heart Failure Danish ICD Study in Patients With Dilated Cardiomyopathy Cardiovascular Magnetic Resonance GUIDEd Insertion of Implantable Cardiac Defibrillator in Dilated CardioMyopathy DCM Precision Medicine Study A Randomized, Controlled Study to Evaluate Algisyl-LVR™ as a Method of Left Ventricular Augmentation for Heart Failure The Genetics of Dilated Cardiomyopathy: A Quebec-Based Study Potential Role of Water-soluble Ubiquinol in Complementary Therapy for Pediatric Dilated Cardiomyopathy A Trial of Autologous Bone Marrow Derived Stem Cells in Paediatric Heart Failure Resynchronization Therapy in Young Patients With and Without CHD Withdrawal of Medication in Recovered DCM Use of Bone Marrow Derived Stem Cell and G-CSF With Circulatory Assistance in the Treatment of DCM The Influence of Atorvastatin on the Parameters of Inflammation and the Function of Left Ventricle Safety and Feasibility of Algisyl-LVR™ as a Method of Left Ventricular Restoration in Patients With DCM Undergoing Open-heart Surgery PUFAs and Left Ventricular Function in Heart Failure 18F-deoxyglucose (FDG) PET-CMD Repetitive Intramyocardial CD34+ Cell Therapy in Dilated Cardiomyopathy (REMEDIUM) Study of Qiliqiangxin Capsule to Treat Dilated Cardiomyopathy Autologous Transplantation of Bone Marrow Mononuclear Stem-Cells by Mini-Thoracotomy Combination of Olmesartan Effect on Myocardial Viability of Patients With Dilated Cardiomyopathy Mesenchymal Stem Cells for Idiopathic Dilated Cardiomyopathy Continues Positive Airway Pressure Treatment for Patients With Dilated Cardiomyopathy and Obstructive Sleep Apnea Pathophysiology of Dilated Cardiomyopathy Multicenter Exploratory Study of Accelerometry in Dilated Cardiomyopathy Transcoronary Infusion of Cardiac Progenitor Cells in Pediatric Dilated Cardiomyopathy Autologous Transplantation of Bone Marrow Mononuclear Stem-Cells for Dilated Cardiomyopathy Clinical and Genetic Examinations of Dilated Cardiomyopathy Simvastatin Therapy in Patients With Dilated Cardiomyopathy. Bone Marrow Derived Adult Stem Cells for Dilated Cardiomyopathy Safety and Efficacy Study of Intramyocardial Stem Cell Therapy in Patients With Dilated Cardiomyopathy Respiratory Muscles Training in Patients With Dilated Cardiomyopathy Myocardial Metabolism in Patients With Dilated Cardiomyopathy Intracoronary Autologous Mesenchymal Stem Cells Implantation in Patients With Ischemic Dilated Cardiomyopathy Orodispersible Minitablets of Enalapril in Children With Heart Failure Due to Dilated Cardiomyopathy Multicenter Study of Immunoadsorption in Dilated Cardiomyopathy Cell Therapy In Dilated Cardiomyopathy Safety and Efficacy Study of Stem Cell Transplantation to Treat Dilated Cardiomyopathy Intracoronary Infusion of Autologous Bone Marrow Cells for Treatment of Idiopathic Dilated Cardiomyopathy Infusion Intracoronary of Mononuclear Autologous Adult no Expanded Stem Cells of Bone Marrow on Functional Recovery in Patients With Idiopathic Dilated Cardiomyopathy and Heart Failure. Nesiritide – Dilated Cardiomyopathy A Study of Impact of Anemia on Morbidity and Mortality in Children With Dilated Cardiomyopathy Defining the Role of Insulin Resistance in ‘Idiopathic’ Dilated Cardiomyopathy Use of Ixmyelocel-T (Formerly Cardiac Repair Cell [CRC] Treatment) in Patients With Heart Failure Due to Dilated Cardiomyopathy (IMPACT-DCM) Use of Ixmyelocel-T (Formerly Catheter-based Cardiac Repair Cell [CRC]) Treatment in Patients With Heart Failure Due to Dilated Cardiomyopathy A Pilot Trial of Ranolazine to Treat Patients With Dilated Cardiomyopathy Coenzyme Q10 Supplementation in Children With Idiopathic Dilated Cardiomyopathy Supramaximal Titrated Inhibition of RAAS in Dilated Cardiomyopathy Intramuscular Injection of Mesenchymal Stem Cell for Treatment of Children With Idiopathic Dilated Cardiomyopathy Honey in Idiopathic Dilated Cardiomyopathy A Clinical Study of Immunoadsorption Therapy for Dilated Cardiomyopathy

Brief Title

Cardiac Biomarkers in Pediatric Cardiomyopathy (PCM Biomarkers)

Official Title

Cardiac Biomarkers in Pediatric Cardiomyopathy

Brief Summary

      Cardiomyopathy is a disease of the heart muscle. It is rare, but it can be serious.
      Cardiomyopathy in children can result in death, disability, heart transplantation or serious
      heart rhythm disorders. Natural substances in the blood called cardiac biomarkers can be
      measured in the laboratory and could be a less invasive way (compared to echocardiograms or
      MRIs) to detect heart dysfunction in children with cardiomyopathy. Little is known about how
      useful and valid cardiac biomarkers are in the diagnosis and determination of the symptoms in
      children with cardiomyopathy. The long-term goal of this project is to study how helpful
      measuring cardiac biomarkers in children with cardiomyopathy is to their doctors in managing
      the care of these patients as well as improving their overall health. Measures of these
      cardiac biomarkers could help doctors in determining how best to care for a child with
      cardiomyopathy, including when to consider heart transplantation as a treatment option.

Detailed Description

      Pediatric cardiomyopathy is a heterogeneous disease with high morbidity and mortality in
      which children often present with fulminant disease leading to death or transplant. Highly
      sensitive and specific cardiac biomarkers or panels of biomarkers, representing different
      pathologic mechanisms or pathways, are the least invasive (a particularly important
      consideration in children) and most-cost-effective approach to the early detection of cardiac
      dysfunction. The long-term goal of this project is to identify such biomarkers in children
      with cardiomyopathy. These findings could represent a major advance in determining the most
      appropriate evidence-based clinical care for these children, including when to consider heart

      The specific aims of this study are:

        1. To determine the ability of established and novel cardiac biomarkers to predict short-
           and long-term outcomes in children with newly diagnosed (incident) dilated
           cardiomyopathy (DCM)

        2. To assess the clinical utility of cardiac biomarkers of collagen metabolism in
           determining the presence of myocardial fibrosis, as established by cardiac MRI (cMRI),
           and left ventricular (LV) diastolic dysfunction, as established by echocardiography in
           both newly diagnosed and existing cases of idiopathic and familial hypertrophic
           cardiomyopathy (HCM) in children.

        3. To determine whether longitudinal changes in cardiac biomarkers are associated with
           worsening heart failure (HF) class in clinically stable children with dilated or
           hypertrophic cardiomyopathy. This study will determine the importance of serological
           biomarkers, in conjunction with cardiac imaging, in the early identification of heart
           disease before cardiac remodeling and functional impairment have become irreversible in
           a pediatric population.

      This is a 5-year prospective study of up to 480 children with either primary dilated or
      hypertrophic cardiomyopathy. The study will have three components: 1) clinical data
      collection by chart review, 2) biospecimen collection and testing, and 3) centralized review
      and measurement of echocardiograms and cMRIs.

Study Type


Primary Outcome

Time to Death

Secondary Outcome

 Time to heart transplant


Dilated Cardiomyopathy

Study Arms / Comparison Groups

 Incident DCM
Description:  A case of dilated cardiomyopathy that presents to the study site for the first time.


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Estimated Enrollment


Start Date

June 2013

Completion Date

June 2022

Primary Completion Date

January 2017

Eligibility Criteria

        Inclusion Criteria:

          -  Patient is alive and has not received a transplant prior to enrollment in the study.

          -  Under age 21 years at age of enrollment

          -  For Group 1 (incident DCM), a case of DCM presenting to a study site within 2 years of
             the original cardiomyopathy diagnosis

          -  Group 2 (incident/recent HCM), a new or existing diagnosis of idiopathic or familial
             HCM with a cMRI within 12 months of diagnosis

          -  Group 3 (prevalent HCM or DCM), any child with a diagnosis of DCM or idiopathic,
             familial, or HCM due to a known disease-causing mutation who has survived
             transplant-free at least 12 months from the date of original cardiomyopathy diagnosis

          -  For all 3 groups, diagnosis of cardiomyopathy must be confirmed by Echocardiographic
             or cMRI criteria

        Exclusion Criteria:

        A patient is not eligible for enrollment if one or more of the following conditions are met
        at the time of presentation with cardiomyopathy:

          -  Any cardiomyopathy diagnosis other than DCM or idiopathic HCM, familial HCM or HCM due
             to a known disease-causing gene

          -  Endocrine disease known to cause heart muscle disease (including infants of diabetic

          -  History of rheumatic fever

          -  Toxic exposures known to cause heart muscle disease (anthracyclines, mediastinal
             radiation, iron overload or heavy metal exposure)

          -  HIV infection or born to an HIV positive mother

          -  Kawasaki disease

          -  Congenital heart defects unassociated with malformation syndromes (e.g., valvular
             heart disease or congenital coronary artery malformations)

          -  Immunologic disease

          -  Invasive cardiothoracic procedures or major surgery during the preceding month, except
             those specifically related to cardiomyopathy including left ventricular assist device
             (LVAD), extracorporeal membrane oxygenator (ECMO), and automatic implantable
             cardioverter defibrillator (AICD) placement

          -  Uremia, active or chronic

          -  Abnormal ventricular size or function that can be attributed to intense physical
             training or chronic anemia

          -  Chronic arrhythmia, unless there are studies documenting inclusion criteria prior to
             the onset of arrhythmia (except a patient with chronic arrhythmia, subsequently
             ablated, whose cardiomyopathy persists after two months is not to be excluded)

          -  Malignancy

          -  Systemic Hypertension

          -  Pulmonary parenchymal or vascular disease (e.g., cystic fibrosis, cor pulmonale, or
             pulmonary hypertension)

          -  Ischemic coronary vascular disease

          -  Association with drugs (e.g., growth hormone, corticosteroids, cocaine) or other
             diseases known to cause hypertrophy




N/A - 20 Years

Accepts Healthy Volunteers



Steven E Lipshultz, MD, , 

Location Countries


Location Countries


Administrative Informations



Organization ID


Responsible Party

Principal Investigator

Study Sponsor

Wayne State University



Study Sponsor

Steven E Lipshultz, MD, Principal Investigator, Wayne State University

Verification Date

October 2020